Long-term survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoinfusion

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2007, Pages 839-846

  Ha, B Y ^a   Ahmed, A ^a   Sze, D Y ^a   Razavi, M K ^a   Simpson, N ^a   Keeffe, E B ^a   Nguyen, M H ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CISPLATIN; CONTRAST MEDIUM; DOXORUBICIN; ETHIODIZED OIL; IOHEXOL;

ADULT; AGE DISTRIBUTION; ANOREXIA; ARTICLE; BLEEDING; CANCER CLASSIFICATION; CANCER STAGING; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG EFFICACY; ETHNICITY; FEMALE; FEVER; GENDER; HAZARD RATIO; HEMATOCRIT; HOSPITAL PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PAIN; PREDICTOR VARIABLE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT OUTCOME; VOMITING;

ADULT; AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 34548314331     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03424.x     Document Type: Article

References (26)

1. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004 127 : S27 34.
2. Nguyen MH, Keeffe EB. Treatment of hepatocellular carcinoma. In : Rusti A, Crawford J, eds. Gastrointestinal Cancer: A companion to Sleisenger & Fordtran's GI and liver diseases. 1st edn. Philadelphia : WB Saunders, 2003 : 605 22.
3. Colleoni M, Audisio RA, De Braud F, et al. Practical considerations in the treatment of hepatocellular carcinoma. Drugs 1998 55 : 367 82.
4. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002 359 : 1734 9.
5. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 35 : 1164 71.
6. de Baere T, Roche A, Amenabar JM, et al. Liver abscess formation after local treatment of liver tumours. Hepatology 1996 23 : 1436 40.
7. Ernst O, Sergent G, Mizrahi D, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumour response. AJR Am J Roentgenol 1999 172 : 59 64.
8. Venook AP, Stagg RJ, Lewis BJ, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990 8 : 1108 14.
9. Kim P, Prapong W, Sze DY, et al. Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion. Tech Vasc Interv Radiol 2002 5 : 127 31.
10. Maeda S, Fujiyama S, Tanaka M, et al. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization. Hepatol Res 2002 23 : 202 10.
11. Puleo S, Mauro L, Gagliano G, et al. Liver damage after transarterial chemoembolization without embolizing agent in unresectable hepatocellular carcinoma. Tumouri 2003 89 : 285 7.
12. Sumie S, Yamashita F, Ando E, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. AJR Am J Roentgenol 2003 181 : 1327 34.
13. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 30.
14. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001 33 : 464 70.
15. Child CG III., Turcotte JG. Surgery in portal hypertension. In : Child CG III., ed. The Liver and Portal Hypertension. Vol. 50. Philadelphia : WB Saunders, 1964.
16. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 60 : 646 9.
17. Hermanek P, Sobin LH. UICC TNM classification of malignant tumours. New York : Springer Verlag, 1992.
18. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998 28 : 751 5.
19. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985 56 : 918 28.
20. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006 131 : 461 9.
21. Ikeda M, Maeda S, Shibata J, et al. Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004 66 : 24 31.
22. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005 11 : 7391 400.
23. Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987 163 : 345 51.
24. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995 332 : 1256 61.
25. Kim KR, Moon HE, Kim KW. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med 2002 80 : 703 14.
26. Clark HP, Carson WF, Kavanagh PV, et al. Staging and current treatment of hepatocellular carcinoma. Radiographics 2005 25 (Suppl. 1 S3 23.